SAN FRANCISCO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executives provided investors with a misleading picture of its financial health and growth prospects. The suit, filed in in the Eastern District of New York, comes after a dramatic stock price decline in August following the company’s earnings report. The firm urges investors in LifeMD who suffered significant losses ...

Shares of telehealth facilitator, drug distributor, and GLP-1 provider Hims & Hers Health Inc. (NYSE: HIMS ) have been on a rollercoaster, especially after retail investors have become much more drawn to this stock thanHi! I'm a passionate investor who has been researching publically traded companies for over 6 years. My primary focus is on identifying great businesses at reasonable prices and holding them for the long term but I also dive into trend following strategies from time to time. While I have a sl ...

Hims & Hers Health Inc. HIMS launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.An estimated 20 million men in the U.S. struggle with low testosterone.Bloomberg earlier reported the update. The telehealth company's latest move comes as its weight-loss drug sales have slowed, impacting its stock performance in recent months. The new offerings aim to bolster its core sexual health services and tap into an underserved market ...

Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone. ...

Hims & Hers Health is launching treatments for low testosterone on its telehealth platform, venturing deeper into a category often marred by stigma, according to its chief executive. ...

股票表现 - Hims & Hers Health公司股价自2024年底被推荐为强烈买入后出现极大波动 [1] - 该股票随后多次实现大幅上涨 [1] 作者背景 - 分析师具有IT行业背景并拥有七年美股投资经验 [1] - 通过管理家族投资组合积累了上市公司基本面分析的专业能力 [1] - 特别擅长科技股分析同时覆盖多个行业领域的机会挖掘 [1]

公司诉讼事件 - 律师事务所Berger Montague PC对LifeMD公司提起集体诉讼 代表2025年5月7日至8月5日期间买入或获得公司股票的投资者 [1] - 诉讼指控公司发布重大虚假和误导性业务声明 夸大其竞争地位且未充分核算客户获取成本上升问题 [3] - 真相披露后公司股价单日暴跌44% 相当于每股下跌5.31美元 [3] 公司业务背景 - LifeMD总部位于纽约 是一家远程医疗服务提供商 直接面向患者提供虚拟护理和药房服务 [2] - 成本上升问题特别集中在RexMD业务部门以及肥胖治疗药物Wegovy和Zepbound相关业务 [3] 投资者权利 - 符合资格的投资者可在2025年10月27日前申请成为首席原告代表 [2] - 律师事务所提供投资者权益咨询渠道 包括高级法律顾问和机构客户服务总监的联系方式 [4][5]

Hims & Hers (NYSE: HIMS ) is no longer just a DTC telehealth storefront. It is fast becoming a targeted health platform with loyal members and rising ARPU. It is also building the foundation to expand intoI am a retired quant with a PhD in mechanical engineering. I started off my professional career as an engineer and eventually transitioned into a hybrid developer/quantative analyst role at the investment arm of one of the nation's largest insurance companies.I ended my career as a fixed income specialist, ...

公司概况 - LifeMD是一家总部位于纽约的直接面向消费者远程医疗公司 提供虚拟医疗服务和药房产品 涵盖男性健康、肥胖治疗和慢性护理等领域 [2] 诉讼事件 - 律师事务所Berger Montague代表在2025年5月7日至2025年8月5日期间购买或收购LifeMD股票的投资者提起集体诉讼 [1] - 投资者可在2025年10月27日前申请成为首席原告代表 [2] 指控内容 - 公司被指控 materially overstated its competitive position 并在提高2025年指引时表现 reckless [3] - 未能适当核算其RexMD部门和肥胖药物产品（包括Wegovy和Zepbound）中不断上升的客户获取成本 [3] 市场影响 - 当公司财务状况真相被揭露时 LifeMD股价在单个交易日下跌44% [3]

公司股价表现 - Teladoc股票价格大幅下跌但存在复苏可能性 [1] - 2025年7月30日股价显示当日微跌0.07% [1] 专业分析视角 - 专家团队通过视频形式深入分析公司表现与未来潜力 [1] - 分析内容涵盖市场趋势和潜在投资机会评估 [1] - 视频发布于2025年8月25日提供最新市场洞察 [1] 机构持仓情况 - The Motley Fool持有并推荐Teladoc Health股票 [2] - 分析师Anand Chokkavelu和Travis Hoium均持有公司头寸 [2] - 分析师Rick Munarriz未持有相关股票头寸 [2]